Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGV001 and CDX-301 in Adjuvant Prostate Cancer
NCT05010200Phase 1Active, not recruiting
- Start
- Jan 2022
- Primary completion
- Jan 2027
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of PGV-001 in prostate cancer (PCa) (3 cohorts). Primary endpoint: Number of adverse events at 191 days. Started Jan 2022; status: active, not recruiting.
02
Drugs
PGV-001
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05010200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05010200.